All Cell Therapies > Cell Therapy Card
Sign in for full access

Enriched bone marrow-derived progenitor cells for heart diseases

The aims of these trials were to investigate whether infused autologous progenitor cells can improve damaged organ function. After bone marrow aspiration, progenitor cells are enriched by centrifugation. The cell suspension consists of a heterogeneous cell population, including hematopoietic, mesenchymal and other progenitor cells, as well as mononuclear cells. These cells were used for treating heart diseases, such as acute myocardial infarction, dilated cardiomyopathy and ischemic heart disease. Intracoronary infusion of progenitor cells can be performed with adequate safety in patients with acute myocardial infarction or chronic heart failure, because the safety profile in treated patients was similar to what is usually expected from a coronary angiogram. Cell treatment was found safe and caused reduced cardiovascular event rate. The treatment had beneficial effects on cardiovascular outcomes, including the recovery of left ventricular function, for at least 2 years, and a positive effect on maladaptive hypertrophy of viable myocardium.

In a pilot trial, 10% of the cells were radioactively labeled prior to injection. Following their distribution demonstrated their homing to the myocardium, preferentially to extensive acute myocardial infarcts characterized by low viability and reduced coronary flow reserve. The amount of progenitor cells retained in the heart decreased progressively with time from the acute myocardial infarction. An additional trial involved pretreatment of chronic postinfarction heart failure patients with targeted cardiac shock wave, in order to increase homing of the bone marrow-derived mononuclear cells transplanted into the patients, and resulted in improvement in left ventricular ejection fraction at 4 months.
See additional Cell Therapies for: Endothelium , Heart
Enriched bone marrow-derived progenitor cells for heart diseases